Abstract
IntroductionMycobacterial infections and HIV is still a relevant topic. Rifampicin complicates antiretroviral drugs management, influencing the prognostic of both conditions. Dolutegravir is a first option drug, but rifampicin diminishes its levels. Doubling dolutegravir doses until two weeks after completing rifampicin treatment has good results. Our goal is to confirm in our daily practice the efficacy and safety of this scheme. MethodsEighteen HIV patients were included with mycobacterial infections. Rifampicin was administered with dolutegravir twice a day as commented. Viral suppression and mycobacterial curation were analyzed until the end of the follow-up. ResultsThirteen from 18 were men, 46 years (interquartile range [IQR]: 38–49), diagnosed of HIV or treated since 1.8 years (IQR: 0.1–12), presenting mainly disseminated mycobacterial infections (11 of 18 cases). From which completed follow-up, 91.6% achieved mycobacterial curation (11 of 12) and 92.9% viral load suppression (13 of 14). ConclusionThe treatment of rifampicin with adjusted dolutegravir doses seems to be a proper combination even in severe immunosuppresed population.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.